Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease

Madrigal’s resmetirom has scored a landmark FDA win, bolstering hopes for a diverse pipeline of drugs for non-alcoholic steatohepatitis.
  1. Katie Kingwell
    View author publications

    You can also search for this author in PubMed  Google Scholar

The non-alcoholic steatohepatitis (NASH) drug development landscape has long been a graveyard of failed programmes. The FDA’s approval of Madrigal’s resmetirom (Rezdiffra), an oral thyroid hormone receptor-beta (THRβ) agonist, now changes things for this potentially fatal liver disease.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 235-237 (2024)

doi: https://doi.org/10.1038/d41573-024-00051-1

Updates & Corrections

  • Update 19 March 2024: The article has been updated to note that the FDA's accelerated approval of resmetirom did not include a requirement for biopsy diagnosis in the prescribing information and to clarify that the phase III trial designed to provide confirmatory evidence to support full approval is ongoing. The status of the phase III trial of pegozafermin has been clarified, and a phase II trial of the combination of ervogastat and clesacostat has been added to the table.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links